CCL17 and pulmonary fibrosis: For instance, it has been reported that CCL17 drives fibroblast activation by enhancing tumor growth factor beta (TGF-β)/Smad signaling, and that anti-CCL17 antibodies attenuate fibrosis in a bleomycin-induced pulmonary fibrosis mouse model [23, 24].